(Q38270068)

1 September 2017

1 reference

title

D-cycloserine augmentation of cognitive behavioral therapy for anxiety disorders: an update (English)

1 reference

cognitive behavioral therapy

1 September 2017

main subject

1 reference

1 reference

Jasper A Smits

4

0 references

Michael W. Otto

object named as

Michael W Otto

series ordinal

2

0 references

author name string

Stefan G Hofmann

series ordinal

1

1 reference

1 September 2017

Mark H Pollack

series ordinal

3

1 reference

1 September 2017

language of work or name

English

0 references

publication date

1 January 2015

1 reference

Current Psychiatry Reports

1 September 2017

published in

1 reference

1 September 2017

volume

17

1 reference

1 September 2017

issue

1

1 reference

1 September 2017

page(s)

532

1 reference

The Efficacy of Cognitive Behavioral Therapy: A Review of Meta-analyses

1 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0532-2

Effects of D-cycloserine on extinction: translation from preclinical to clinical work

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0532-2

D-Cycloserine as an augmentation strategy for cognitive behavioral therapy of anxiety disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0532-2

D-cycloserine as an augmentation strategy for cognitive behavioral therapy for anxiety disorders: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0532-2

Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0532-2

Augmentation of exposure therapy with D-cycloserine for social anxiety disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0532-2

A randomized controlled trial of D-cycloserine enhancement of exposure therapy for social anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0532-2

Efficacy of d-cycloserine for enhancing response to cognitive-behavior therapy for panic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0532-2

D-cycloserine does not improve but might slightly speed up the outcome of in-vivo exposure therapy in patients with severe agoraphobia and panic disorder in a randomized double blind clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0532-2

D-cycloserine augmented exposure therapy for obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0532-2

Augmentation of behavior therapy with D-cycloserine for obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0532-2

A preliminary study of D-cycloserine augmentation of cognitive-behavioral therapy in pediatric obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0532-2

Facilitation of fear extinction by D-cycloserine: theoretical and clinical implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0532-2

A randomized placebo-controlled trial of D-cycloserine and exposure therapy for posttraumatic stress disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0532-2

A randomized, double-blind evaluation of D-cycloserine or alprazolam combined with virtual reality exposure therapy for posttraumatic stress disorder in Iraq and Afghanistan War veterans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0532-2

D-Cycloserine as an augmentation strategy with cognitive-behavioral therapy for social anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0532-2

Chronic treatment with antidepressants affects glycine/NMDA receptor function: behavioral evidence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0532-2

Reconsolidation and extinction of conditioned fear: inhibition and potentiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0532-2

D-cycloserine for treating anxiety disorders: making good exposures better and bad exposures worse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0532-2

D-cycloserine facilitates context-specific fear extinction learning

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0532-2

D-cycloserine enhancement of exposure therapy for social anxiety disorder depends on the success of exposure sessions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0532-2

D-cycloserine enhancement of fear extinction is specific to successful exposure sessions: evidence from the treatment of height phobia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0532-2

Augmentation of exposure therapy with post-session administration of D-cycloserine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0532-2

The promise of extinction research for the prevention and treatment of anxiety disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0532-2

Effects of D-cycloserine on extinction of conditioned freezing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0532-2

A high-throughput clinical assay for testing drug facilitation of exposure therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0532-2

D-cycloserine augmentation of cognitive behavioral group therapy of social anxiety disorder: prognostic and prescriptive variables

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0532-2

Prescriptive variables for d-cycloserine augmentation of exposure therapy for posttraumatic stress disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0532-2

Yohimbine enhancement of exposure therapy for social anxiety disorder: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0532-2

Glucocorticoids enhance in vivo exposure-based therapy of spider phobia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0532-2

Cognitive enhancers for the treatment of anxiety disorders

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25413638

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S11920-014-0532-2

1 reference

Dimensions Publication ID

1 September 2017

1040251061

0 references

1 reference